Data from Frequency–Volume Charts versus Symptom Scores and Quality of Life Score in Men with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

2001 ◽  
Vol 39 (1) ◽  
pp. 42-47 ◽  
Author(s):  
Ger E.P.M. van Venrooij ◽  
Ger E.P.M. van Venrooij ◽  
Mardy D. Eckhardt ◽  
Mardy D. Eckhardt ◽  
Karel W.H. Gisolf ◽  
...  
Urologiia ◽  
2018 ◽  
Vol 1_2018 ◽  
pp. 53-61 ◽  
Author(s):  
D.Yu. Pushkar Pushkar ◽  
A.N. Bernikov Bernikov ◽  
L.A. Khodyreva Khodyreva ◽  
A.A. Dudareva Dudareva ◽  
S.Kh. Al'-Shukri Al'-Shukri ◽  
...  

e-CliniC ◽  
2015 ◽  
Vol 3 (1) ◽  
Author(s):  
Cristie S. Mandang ◽  
Richard A. Monoarfa ◽  
Billy Salem

Abstract: Benign prostatic hyperplasia (BPH) is a disease that is rarely life-threatening, but resulting in annoying complaints and decreasing the quality of life of the patients. BPH is found in older men. BPH patients who come for treatment are usually accompanied with lower urinary tract symptoms (LUTS). BPH patients with LUTS symptoms usually come to the clinic when they feel that the symptoms are bothering their daily-lives, therefore, decreasing the quality of life (QoL). BPH is caused by many factors, as follows: knowledge, economic, social, or cultural factors. To determine the severity of BPH with LUTS, we used the International Prostate Symptom Scoring Score (IPSS) and 1 question about the quality of life. Based on the results of cross-sectional study in December 2014 we obtained 37 patients as samples. Most patients belonged to the age group of 70-79 years (62.2%). The majority of respondents had severe degree of IPSS score (20 patients, 54.1%). The value of QoL scores showed that 10 patients (27%) were not happy with their quality of life. The Spearman correlation test was used to find whether there was a correlation between the IPSS score and Quality of Life (QoL) of BPH patients with LUTS symptoms. There was a significant correlation (p < 0.005) between IPSS-QoL (r = 0.481). The reason that patients with symptoms of BPH LUTS came the surgical clinic of Prof. Dr R. D. Kandou Hospital Manado with severe symptoms and decreases QoL was their lack of knowledge about BPH.Keywords: BPH, LUTS, IPSS, QoL, ManadoAbstrak: Hiperplasia prostat jinak atau Benign Prostatic Hyperplasia (BPH) merupakan penyakit yangjarang mengancamjiwa tetapi cukup memberikan keluhan yang menjengkelkan dan menurunkan kualitas hidup penderitanya dan sering ditemukan pada pria usia lanjut. Pasien BPH yang datang berobat biasanya disertai dengan LUTS (lower urinary tract symptoms). Pasien BPH dengan gejala LUTS yang mencari pengobatan medis biasanya datang pada saat dirinya merasa bahwa gejala yang dirasakan sudah cukup menggangu aktivitas sehari-hari atau dengan kata lain, mengganggu kualitas hidupnya. Keadaan seperti ini disebabkan oleh banyak faktor, antara lain faktor pengetahuan, ekonomi, atau sosial budaya. Untuk menentukan derajat berat ringannya BPH yang disertai dengan gejala LUTS, digunakan skoring International Prostate Symptom Score (IPSS) dan 1 pertanyaan mengenai kualitas hidup. Berdasarkan hasil penelitian potong lintang yang dilakukan selama bulan Desember 2014 didapatkan 37 sampel. Insiden BPH terbanyak berada pada kisaran umur 70-79 tahun sebanyak 23 pasien (62,2%). Derajat BPH yang paling sering ialah derajat berat sebanyak 20 pasien (54,1%). Nilai skor kualitas hidup yang sering dirasakan pasien menunjukkan bahwa 10 pasien (27%) merasa tidak senang dengan kualitas hidupnya. Hasil uji korelasi antara IPSS-QOL didapatkan bermakna (p<0,005), dengan nilai r = 0,481. Faktor yang menjadi alasan mengapa pasien-pasien BPH dengan gejala LUTS yang berobat di Poli Bedah RSUP Prof. Dr. 490Mandang, Monoarfa, Salem: Hubungan antara skor...R. D. Kandou Manado datang dengan gejala yang berat dan kualitas hidup tidak senang ialah kurangnya pengetahuan mengenai BPH itu sendiri.Kata kunci: BPH, LUTS, IPSS, QOL, Manado


2017 ◽  
Vol 10 (5) ◽  
pp. 464-470 ◽  
Author(s):  
D Porru ◽  
C Di Franco ◽  
V Bobbi ◽  
C Tinelli ◽  
B Rovereto

Aim: The aim of this pilot clinical trial was to determine if Odyliresin ( Iresine celosia), a cytochrome-flavoprotein with a powerful anti-oxidant action on cells, has a therapeutic effect on benign prostatic hyperplasia-related lower urinary tract symptoms, reducing symptoms and prostate volume, improving the patient’s quality of life and eventually limiting the number of patients who require surgery or endoscopy after medical treatment. Methods: Thirty patients with benign prostatic hyperplasia-related lower urinary tract symptoms were recruited and followed up. Primary outcomes were assessed using International Prostate Symptom Score symptom questionnaires, quality of life score, examination, prostate-specific antigen, transrectal ultrasound, uroflowmetry with post-void residual volume. Once recruited, patients were assigned for treatment: alpha-antagonist (alfuzosin 10 mg)+Odyliresin ( Iresine celosia) 2 ml, 20 drops once daily. Results: The results for quantitative variables were expressed as mean values and standard deviation as they were all normally distributed (Shapiro–Wilk test). The study included 30 patients with an average age of 68 years (range 56–80 years). The statistical analysis of data reports significant improvement of mean values of maximum urinary flow rate (+1.2, p=0.050), average flow rate (+0.47, p>0.002), International Prostate Symptom Score (–4.8, p=0.000), quality of life (–1.4, p=0.000), total prostatic volume (–1.7, p=0.000), prostatic adenoma (–6.9, p=0.000) and post-void residual volume (–17.8, p>0.004) between baseline and 12 months after treatment. No patient had acute urinary retention during treatment or need for benign prostatic hyperplasia-related surgery at the end of the 12-month treatment. Conclusions: All patients with benign prostatic hyperplasia-related lower urinary tract symptoms received both alphalitic and Odyliresin treatment. Clinical parameters and uroflowmetry parameters significantly improved, adenoma volume and post-void residual volume were significantly reduced at 12 months. This is the first clinical experience with Iresine celosia, a phytotherapeutic agent with no scientifically proven clinical efficacy so far in benign prostatic hyperplasia.


Sign in / Sign up

Export Citation Format

Share Document